Loading…
Life Sciences Jobs and Investment Act of 2011
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 6,662 other HR bills in the 112th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (9)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2012 · fourth_quarter · Health Issues
S. 248, to allow an earlier start for state health care coverage innovation waivers under the Patient Protection and Affordable Care Act; to Health, Education, Labor, & Pensions. S. 1410, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. S. 1468, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program. S. 2113, to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health; to Health, Education, Labor, & Pensions. S. 2119, to establish a pilot program to address overweight/obesity among children from birth to age five in child care settings and to encourage parental engagement; to Health, Education, Labor, & Pensions. S. 2516, to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars. H.R. 2276, to require the director of the U.S. Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes. H.R. 2632, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. H.R. 2741, to amend title XVIII of the Social Security Act to reduce the occurrence of diabetes in Medicare beneficiaries by extending coverage under Medicare for medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing Type 2 diabetes. H.R. 2787, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program. H.R. 2799, to amend the Public Health Service Act to authorize grants to provide treatment for diabetes in minority communities. H.R. 4604, to amend the Public Health Service Act to provide for a national program to conduct and support activities toward the goal of significantly reducing the number of cases of overweight and obesity among individuals in the United States.
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2012 · fourth_quarter · Taxation/Internal Revenue Code
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
Client expense: $520,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Health Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S. 1410; the Life Sciences Jobs and Investment Act of 2011, biosimiliars; prescription and generic drug user fees legislation; H.R. 6160, Stop Tampering of Prescription Pills Act of 2012.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Pharmacy
General issues affecting the pharmaceutical industry and bioequivelence. (Generic pharmaceutical user fee act; H.R. 5651.) The Life Sciences Jobs and Investment Act (S. 1410; H.R. 2632)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Health Issues
The Life Sciences Jobs and Investment Act of 2011. (S. 1410; H.R. 2632)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
Life Sciences Jobs and Investment Act (S. 1410; H.R. 2632).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES
2012 · third_quarter · Health Issues
S. 248, to allow an earlier start for state health care coverage innovation waivers under the Patient Protection and Affordable Care Act; to Health, Education, Labor, & Pensions. S. 1410, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. S. 1468, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program; to Finance. S. 2113, to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health; to Health, Education, Labor, & Pensions. S. 2119, to establish a pilot program to address overweight/obesity among children from birth to age five in child care settings and to encourage parental engagement; to Health, Education, Labor, & Pensions. S. 2516, to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars. H.R. 2276, to require the director of the U.S. Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes; jointly to Judiciary and Energy & Commerce. H.R. 2632, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. H.R. 2741, to amend title XVIII of the Social Security Act to reduce the occurrence of diabetes in Medicare beneficiaries by extending coverage under Medicare for medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing Type 2 diabetes; jointly to Energy & Commerce and Ways & Means. H.R. 2787, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program; jointly to Energy & Commerce and Ways & Means. H.R. 2799, to amend the Public Health Service Act to authorize grants to provide treatment for diabetes in minority communities; to Energy & Commerce. H.R. 4604, to amend the Public Health Service Act to provide for a national program to conduct and support activities toward the goal of significantly reducing the number of cases of overweight and obesity among individuals in the United States.
2012 · third_quarter · Taxation/Internal Revenue Code
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
Client expense: $510,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Taxation/Internal Revenue Code
Life Sciences Jobs and Investment Act (S. 1410; H.R. 2632).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
The Life Sciences Jobs and Investment Act of 2011. (S. 1410; H.R. 2632)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Pharmacy
General issues affecting the pharmaceutical industry and bioequivelence. (Generic pharmaceutical user fee act; H.R. 5651.) The Life Sciences Jobs and Investment Act (S. 1410; H.R. 2632)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Taxation/Internal Revenue Code
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES
2012 · third_quarter · Health Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S. 1410; the Life Sciences Jobs and Investment Act of 2011, biosimiliars; prescription and generic drug user fees legislation
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Health Issues
S. 248, to allow an earlier start for state health care coverage innovation waivers under the Patient Protection and Affordable Care Act; to Health, Education, Labor, & Pensions. S. 1410, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. S. 1468, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program. S. 2113, to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health; to Health, Education, Labor, & Pensions. S. 2119, to establish a pilot program to address overweight/obesity among children from birth to age five in child care settings and to encourage parental engagement; to Health, Education, Labor, & Pensions. S. 2516, to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars. H.R. 2276, to require the director of the U.S. Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes. H.R. 2632, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. H.R. 2741, to amend title XVIII of the Social Security Act to reduce the occurrence of diabetes in Medicare beneficiaries by extending coverage under Medicare for medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing Type 2 diabetes. H.R. 2787, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program. H.R. 2799, to amend the Public Health Service Act to authorize grants to provide treatment for diabetes in minority communities. H.R. 4604, to amend the Public Health Service Act to provide for a national program to conduct and support activities toward the goal of significantly reducing the number of cases of overweight and obesity among individuals in the United States.
2012 · second_quarter · Science/Technology
H.R. 2632, S.1410 - Life Science Jobs and Investment Act, including tax incentives General issues related to technology and life sciences S. 1866, American Growth, Recovery, Empowerment, and Entrepreneurship Act (AGREE Act)
Client expense: Not reported · Firm income: $20,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), SENATE, Treasury, Dept of, White House Office
2012 · second_quarter · Taxation/Internal Revenue Code
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
Client expense: $480,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Taxation/Internal Revenue Code
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES
2012 · second_quarter · Taxation/Internal Revenue Code
Life Sciences Jobs and Investment Act (S. 1410; H.R. 2632).
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Health Issues
The Life Sciences Jobs and Investment Act of 2011. (S. 1410; H.R. 2632)
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Pharmacy
General issues affecting the pharmaceutical industry and bioequivelence. (Generic pharmaceutical user fee act; H.R. 5651.) The Life Sciences Investment Act (S. 1410; H.R. 2632)
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Health Issues
General health IT and electronic medical records issues; HR 2925, Medicare Common Access Card Act; HR 2632 Life Sciences Jobs and Investment Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Health Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S. 1410; the Life Sciences Jobs and Investment Act of 2011, biosimiliars; prescription and generic drug user fees legislation
Client expense: Not reported · Firm income: $32,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Health Issues
S. 248, to allow an earlier start for state health care coverage innovation waivers under the Patient Protection and Affordable Care Act; to Health, Education, Labor, & Pensions. S. 1410, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. S. 1468, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program. S. 2113, to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health; to Health, Education, Labor, & Pensions. S. 2119, to establish a pilot program to address overweight/obesity among children from birth to age five in child care settings and to encourage parental engagement; to Health, Education, Labor, & Pensions. H.R. 2276, to require the director of the U.S. Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes. H.R. 2632, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. H.R. 2741, to amend title XVIII of the Social Security Act to reduce the occurrence of diabetes in Medicare beneficiaries by extending coverage under Medicare for medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing Type 2 diabetes. H.R. 2787, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program. H.R. 2799, to amend the Public Health Service Act to authorize grants to provide treatment for diabetes in minority communities.
2012 · first_quarter · Science/Technology
H.R. 2632, S.1410 - Life Science Jobs and Investment Act, including tax incentives General issues related to technology and life sciences
Client expense: Not reported · Firm income: $20,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2012 · first_quarter · Health Issues
General health IT and electronic medical records issues; HR 2925, Medicare Common Access Card Act; HR 2632 Life Sciences Jobs and Investment Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Taxation/Internal Revenue Code
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Health Issues
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674); Generic Drug and Biosimilar User Fee Act of 2012 (H.R. 3998).
Client expense: $700,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Taxation/Internal Revenue Code
Life Sciences Jobs and Investment Act (H.R. 2632, S. 1410).
Client expense: $700,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Health Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S.1410; the Life Sciences Jobs and Investment Act of 2011; biosimiliars; prescription and generic drug user fees legislation
Client expense: Not reported · Firm income: $32,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Taxation/Internal Revenue Code
Life Sciences Jobs and Investment Act (S. 1410; H.R. 2632).
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Pharmacy
General issues affecting the pharmaceutical industry and bioequivelence. (Generic pharmaceutical user fee act.) The Life Sciences Investment Act (S. 1410; H.R. 2632)
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Health Issues
The Life Sciences Jobs and Investment Act of 2011. (S. 1410; H.R. 2632)
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Voiced support HR 2632, the Life Science Jobs and Investment Act
Client expense: Not reported · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO)
2011 · fourth_quarter · Taxation/Internal Revenue Code
Support Life Sciences Job & Investment Act (HR 2632). Support repeal of medical device tax. Support extension of Therapeutic Discovery Project program. Support extension of R&D tax credit.
Client expense: $180,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2011 · fourth_quarter · Health Issues
S. 248, to allow an earlier start for state health care coverage innovation waivers under the Patient Protection and Affordable Care Act; to Health, Education, Labor, & Pensions. S. 1410, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. S. 1468, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program. H.R. 2276, to require the director of the U.S. Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes. H.R. 2632, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. H.R. 2741, to amend title XVIII of the Social Security Act to reduce the occurrence of diabetes in Medicare beneficiaries by extending coverage under Medicare for medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing Type 2 diabetes. H.R. 2787, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program. H.R. 2799, to amend the Public Health Service Act to authorize grants to provide treatment for diabetes in minority communities.
Client expense: $110,000 · Firm income: Not reported
2011 · fourth_quarter · Taxation/Internal Revenue Code
H.R. 2632 - Life Sciences Jobs and Investment Act of 2011
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · fourth_quarter · Health Issues
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · fourth_quarter · Taxation/Internal Revenue Code
Life Sciences Jobs and Investment Act (H.R. 2632, S. 1410)
Client expense: $700,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
2011 · fourth_quarter · Health Issues
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674)
Client expense: $700,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
2011 · fourth_quarter · Science/Technology
H.R. 2632, S.1410 - Life Science Jobs and Investment Act, including tax incentives
Client expense: Not reported · Firm income: $20,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2011 · fourth_quarter · Health Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S.1410, the Life Sciences Jobs and Investment Act of 2011
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · fourth_quarter · Taxation/Internal Revenue Code
Life Sciences Jobs and Investment Act (S. 1410; H.R. 2632).
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · fourth_quarter · Pharmacy
General issues affecting the pharmaceutical industry and bioequivelence. The Life Sciences Investment Act (S. 1410; H.R. 2632)
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · fourth_quarter · Health Issues
The Life Sciences Jobs and Investment Act of 2011. (S. 1410; H.R. 2632)
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Support Medical Device Excise Tax Repeal Efforts Support HR 1988, the Theraputic Tax Credit Extension Act of 2011 Support HR 2632, the Life Science Jobs and Investment Act
Client expense: $40,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2011 · third_quarter · Health Issues
S. 248, to allow an earlier start for state health care coverage innovation waivers under the Patient Protection and Affordable Care Act; to Health, Education, Labor, & Pensions. S. 1410, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. S. 1468, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program. H.R. 2276, to require the director of the U.S. Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes. H.R. 2632, to amend the Internal Revenue Code of 1986 to provide incentives for life sciences research. H.R. 2741, to amend title XVIII of the Social Security Act to reduce the occurrence of diabetes in Medicare beneficiaries by extending coverage under Medicare for medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing Type 2 diabetes. H.R. 2787, to amend title XVIII of the Social Security Act to improve access to diabetes self-management training by authorizing certified diabetes educators to provide diabetes self-management training services, including as part of telehealth services, under Part B of the Medicare program. H.R. 2799, to amend the Public Health Service Act to authorize grants to provide treatment for diabetes in minority communities.
Client expense: $110,000 · Firm income: Not reported
2011 · third_quarter · Health Issues
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · third_quarter · Science/Technology
H.R. 2632, S.1410 - Life Science Jobs and Investment Act, including tax incentives
Client expense: Not reported · Firm income: $20,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2011 · third_quarter · Health Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S.1410, the Life Sciences Jobs and Investment Act of 2011
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| PA |
| Charles W. Dent | Republican | PA |
| Jason Altmire | Democratic | PA |
| Jim Gerlach | Republican | PA |
| Lamar Smith | Republican | TX |
| Michael G. Fitzpatrick | Republican | PA |
| Patrick Meehan | Republican | PA |
| Robert A. Brady | Democratic | PA |
Client expense: $110,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)